About ObNowa
Pharmaceutical disciplinefor the aestheticsconsultation room.
ObNowa Pharma is a global pharmaceutical development company headquartered in Warsaw, Poland, focused on medical aesthetics. We develop science-driven treatments across hair growth and neurotoxin-based aesthetics, with the rigour of drug development and a clear focus on meaningful outcomes for patients.
Mission
To earn the trust of patients and physicians in medical aesthetics — with candidates developed to pharmaceutical standards and evidence that speaks before marketing does.
Vision
A global house of aesthetic medicine where hair-growth and aesthetic-neurotoxin science are developed — and judged — like medicine.
The ObNowa story
A confluence of two sciences.
Two complementary areas of scientific focus. One global pharmaceutical development company, headquartered in Poland — where selected science becomes a focused medical-aesthetics development portfolio.
Aneira Pharma
Hair-growth science
Built on the biology of hair follicles and the hair growth cycle, the licensed hair-growth programs target pattern hair loss and eyebrow density.
Object Pharma
Neurotoxin science
Object Pharma's botulinum toxin science and development expertise underpin two complementary programs: a bio-comparable program designed around established performance standards, and a bio-better program exploring differentiated characteristics.
Headquarters & foundation
Headquartered in Poland. Developing globally.
ObNowa is headquartered in Warsaw, inside the European Union's single regulatory and commercial space. Poland pairs one of Europe's largest life-science talent bases with competitive development economics — allowing capital to flow toward evidence generation. From this European base, ObNowa develops programs to global regulatory standards, with geographic strategies determined by the rights and development pathway of each asset.
- Development designed to meet global regulatory expectations, including EMA requirements
- EU GMP manufacturing via European CDMO partnerships
- Access to 27-member-state single market from one base
- Deep clinical-trial infrastructure and investigator networks
How we operate
Four principles, no exceptions.
01
Patients first
We develop medicines for patients — grounded in evidence, clinical relevance and the standards physicians can trust.
02
Evidence before narrative
Evidence comes first. Claims follow data, never the reverse. Where programs are early, we say so — clearly and without overstatement.
03
Global Standards
Headquartered in Warsaw within the European Union, with European pharmaceutical expertise embedded in our development approach — and programs developed to global standards.
04
Capital discipline
A focused, development-stage portfolio keeps capital close to the science — prioritising the programs and development activities with the greatest potential to create value.